First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer

समान संसाधन

• Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer
  द्वारा: Jeong, Byeong-Ho, और अन्य
  प्रकाशित: (2019)
• Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
  द्वारा: Liam, Chong-Kin
  प्रकाशित: (2017)
• Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer
  द्वारा: Aguiar, Pedro N., और अन्य
  प्रकाशित: (2018)
• Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?
  द्वारा: Green, John A.
  प्रकाशित: (2018)
• The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer
  द्वारा: Gil, Hyun-Il, और अन्य
  प्रकाशित: (2020)